Pharma Company Behind Miracle COVID Pill Is Marking Up Price 4,000%

Pharma Company Behind Miracle COVID Pill Is Marking Up Price 4,000%


Molnupiravir was supposed to be the next big breakthrough in getting us back to something resembling normalcy. If only we could afford it.

The Merck-marketed antiviral drug reduced hospitalizations for COVID-19 by 50 percent in a study of 775 high-risk patients.

According to the Daily Mail, 7.3 percent of those taking molnupiravir were hospitalized compared to 14.1 percent who received a placebo. While eight patients in the placebo group died, none from the molnupiravir group did.

Trending: “I told you so!”…Senator Rand Paul Calls Fauci Out for Lying to Congress After NIH Confirms They Funded Wuhan’s Gain of Function Research [Video]

The drug was developed with massive government subsidies by a company licensed by Ridgeback Biotherapeutics. Ridgeback sold the rights to Merck in 2020.

The Intercept reported that molnupiravir was initially investigated as a treatment for Venezuelan equine encephalitis, although it’s now found a far more useful application. As a pill,

Continue reading

You Might Like

 

Join the conversation!

Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!

Thanks for sharing!
Send this to a friend